Ginkgo Bioworks Holdings (DNA) Gross Margin (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) posted Gross Margin of 84.09% for Q1 2026, up 93.96% on a QoQ basis from 43.36% in Q4 2025, and down 521.0% year-over-year from 19.97% in Q1 2025.
Ginkgo Bioworks Holdings (DNA) Gross Margin (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings' Gross Margin history runs 7 years deep, the most recent figure standing at 84.09% for Q1 2026.
- Quarterly Gross Margin fell 521.0% year-over-year to 84.09% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 74.83% (down 2073.0% YoY) and the FY2025 annual result came in at 83.02%, down 1434.0% from the prior year.
- Gross Margin was 84.09% for Q1 2026 at Ginkgo Bioworks Holdings, up from 43.36% in the prior quarter.
- Across five years, Gross Margin topped out at 256.03% in Q4 2022 and bottomed at 43.36% in Q4 2025.
- A 5-year average of 96.2% and a median of 89.3% in 2025 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2022 — Gross Margin soared 15928 bps — and 2023, when it slumped 15295 bps.
- Ginkgo Bioworks Holdings' Gross Margin stood at 256.03% in 2022, then plunged by 60 bps to 103.08% in 2023, then retreated by 8 bps to 95.28% in 2024, then sank by 54 bps to 43.36% in 2025, then surged by 94 bps to 84.09% in 2026.
- Business Quant data shows DNA's Gross Margin at 84.09% in Q1 2026, 43.36% in Q4 2025, and 78.95% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Ginkgo Bioworks Holdings | 517.16 Mn | 373.30 Mn | 16.38 Mn | 84.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84.09% |
| Dec 31, 2025 | 43.36% |
| Sep 30, 2025 | 78.95% |
| Jun 30, 2025 | 89.15% |
| Mar 31, 2025 | 89.30% |
| Dec 31, 2024 | 95.28% |
| Sep 30, 2024 | 97.74% |
| Jun 30, 2024 | 96.59% |
| Mar 31, 2024 | 100.00% |
| Dec 31, 2023 | 103.08% |
| Sep 30, 2023 | 87.51% |
| Jun 30, 2023 | 80.06% |
| Mar 31, 2023 | 77.90% |
| Dec 31, 2022 | 256.03% |
| Sep 30, 2022 | 62.87% |
| Jun 30, 2022 | 98.31% |
| Mar 31, 2022 | 95.19% |
| Dec 31, 2021 | 96.75% |
| Sep 30, 2021 | 75.68% |
| Jun 30, 2021 | 64.96% |